ClinicalTrials.gg
CompletedNCT05532358Updated Mar 23, 2023

A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

A Phase 1 interventional study of anle138b (TEV-56286) and Fluvoxamine 100 mg QD for 5 days in Healthy Volunteers, sponsored by MODAG GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by MODAG GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Multiple System Atrophy with a site in United Kingdom — 4 open to participants now, 5 under way, 1 of them phase 3. Multiple System Atrophy · United Kingdom.

Enrollment
13th of 16
54 · median 74
Started
2022
with 5 others
Phase 1
4 of 19
1 open now
Registered
16th of 19
by date
Lead sponsor
3 of 19
MODAG GmbH

Among the 19 studies in Multiple System Atrophy with a site in United Kingdom, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2022, is one of 4 in phase 1, and was the 16th registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

4 of the 19 studies in Multiple System Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Multiple System Atrophy with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).

Read the detailed description

This a 2-part DDI study that will assess the CYP1A2 and CYP3A4 perpetrator interaction potential of TEV-56286 single dose and multiple dose, using caffeine and midazolam as substrates and CYP1A2 victim potential of TEV-56286 (anle138b) at steady state induction using fluvoxamine as inhibitor [1,2].The estimated time from screening until the follow-up visit is approximately up to 8 weeks for each subjects.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • anle138b (TEV-56286)
  • alpha-Synuclein
  • Oligomer modulator
  • Multiple System Atrophy
  • Parkinson Disease
  • Alzheimer Disease
  • Neurodegenerative diseases
  • Tauopathies
  • Amyloid
  • Drug-drug interaction
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or healthy females of non-
  • Must provide written for participation in the study and must be able to understand the study requirements
  • (BMI) 18.5 to 32.0 kg/m2.
  • Must agree to adhere to the requirements defined in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Serious adverse reaction or serious to any drug or formulation e.g. fluvoxamine, caffeine, midazolam or benzodiazepines or any of its excipients, or a known drug hypersensitivity idiosyncratic reaction to TEV-56286, or one of its excipients
  • History of cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, metabolic diseases or a history of any illness that, in the opinion of the investigator, might pose additional risk to the subject by participation in the study or confound the results of the study
  • Acute infection and/or antibiotic treatment within 28 days of Day 1
  • Major trauma or surgery in the 2 months before screening or at any time between screening and Day 1, or surgery scheduled during the study or follow up period
  • History of or treatment of malignancy in the last 5 years
  • History of suicidal ideation with an intent and/or plan and behaviour based upon either clinical history or source documents
  • Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, or long syndrome, or a personal history of syncope or previous treatment for high blood pressure (BP). Abnormality of 12-lead that may, in the opinion of the investigator, interfere with study participation
  • Any procedure or disorder that may interfere with drug absorption, distribution, metabolism, or excretion
  • Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator.
  • Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days before study medication administration or within 5 half-lives whichever is longer.
  • Subjects who are taking, or have taken hormonal (e.g., oral, patch, injectable or intrauterine device) hormone replacement therapy (HRT) or a long-acting injectable hormonal within 4 weeks prior to first dose of IMP
  • Subjects who are taking, or have taken any inducer of CYP 1A2, within 28 days prior to Day -2
  • History of any drug or alcohol abuse in the past 2 years
  • Current smokers and those who have smoked within the last 12 months or has a positive urine cotinine test
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Subjects with a previous history of difficulty in swallowing tablets or capsules, or an anticipated problem with swallowing a large number of capsules
  • Subjects who have consumed grapefruit, grapefruit juice, Seville oranges, pomelo-containing products, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, and mustard) and charbroiled meats within the 14 days prior to Day -2
  • Subjects who are unwilling to comply with the restricted use of caffeinated beverages (e.g. coffee, tea, cola) during the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    anle138b (TEV-56286) as perpetrator (part I)

    Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days) Victim drugs: Caffeine 200 mg Midazolam 2 mg

    Drug: anle138b (TEV-56286)

  • Experimental
    anle138b (TEV-56286) as victim (part II)

    Drug: fluvoxamine 100 mg QD for 5 days Victim drug: TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine

    Drug: Fluvoxamine 100 mg QD for 5 days

Interventions

  • Anle138b (TEV-56286) as perpetrator

    Also known as: Caffeine, Midazolam, Fluvoxamine

  • Anle138b (TEV-56286) as victim

    Also known as: TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine

06

What researchers measure

Primary outcomes

  1. Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: Cmax for caffeine.

    Time frame: Day 1

  2. Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC(0-inf) for caffeine.

    Time frame: Day 1

  3. Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC (0-last) for caffeine.

    Time frame: Day 1

  4. Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: Cmax for midazolam.

    Time frame: Day 1

  5. Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC(0-inf) for midazolam.

    Time frame: Day 1

  6. Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC (0-last) for midazolam.

    Time frame: Day 1

  7. Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).

    Cmax for caffeine.

    Time frame: Day 3

  8. Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC(0-inf) for caffeine.

    Time frame: Day 3

  9. Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC (0-last) for caffeine.

    Time frame: Day 3

  10. Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).

    Cmax for midazolam

    Time frame: Day 3

  11. Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC(0-inf) for midazolam.

    Time frame: Day 3

  12. Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC (0-last) for midazolam.

    Time frame: Day 3

  13. Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: Cmax for caffeine.

    Time frame: Day 18

  14. Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).

    AUC(0-inf) for caffeine.

    Time frame: Day 18

  15. Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC (0-last) for caffeine.

    Time frame: Day 18

  16. Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: Cmax for midazolam.

    Time frame: Day 18

  17. Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC(0-inf) for midazolam.

    Time frame: Day 18

  18. Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).

    PK parameter: AUC (0-last) for midazolam.

    Time frame: Day 18

  19. Oral pharmacokinetics (PK) of TEV-56286 without fluvoxamine in healthy volunteers after repeated administration in the fasted state (Part II).

    PK parameter: Cmax for TEV-56286.

    Time frame: Day 14

  20. Oral pharmacokinetics (PK) of TEV-56286 without fluvoxamine in healthy volunteers after repeated administration in the fasted state (Part II).

    PK parameter: AUC(0-tau) for TEV-56286.

    Time frame: Day 14

  21. Oral pharmacokinetics (PK) of TEV-56286 in healthy volunteers after repeated co-administration with fluvoxamine in the fasted state.

    PK parameter: Cmax for TEV-56286 (Part II).

    Time frame: Day 19

  22. Oral pharmacokinetics (PK) of TEV-56286 in healthy volunteers after repeated co-administration with fluvoxamine in the fasted state.

    PK parameter: AUC(0-tau) for TEV-56286 (Part II).

    Time frame: Day 19

Secondary outcomes

  1. Oral pharmacokinetics (PK) of substrates caffeine and midazolam

    PK parameter: Tmax

    Time frame: Day 1, Day 3, Day 18

  2. Oral pharmacokinetics (PK) of substrates caffeine and midazolam

    PK parameter: Tlag

    Time frame: Day 1, Day 3, Day 18

  3. Oral pharmacokinetics (PK) of substrates caffeine and midazolam

    PK parameter: lambda-z

    Time frame: Day 1, Day 3, Day 18

  4. Oral pharmacokinetics (PK) of substrates caffeine and midazolam

    PK parameter: T1/2

    Time frame: Day 1, Day 3, Day 18

  5. Oral pharmacokinetics (PK) of substrates caffeine and midazolam

    PK parameter: CL/F

    Time frame: Day 1, Day 3, Day 18

  6. Oral pharmacokinetics (PK) of substrates caffeine and midazolam

    PK parameter: Vz/F

    Time frame: Day 1, Day 3, Day 18

  7. Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine

    PK parameter: Tmax

    Time frame: Day 19

  8. Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine

    PK parameter: lambda-z

    Time frame: Day 19

  9. Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine

    PK parameter: T1/2

    Time frame: Day 19

  10. Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine

    PK parameter: CL/F

    Time frame: Day 19

  11. Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine

    PK parameter: Vz/F

    Time frame: Day 19

  12. Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam

    PK parameter: Tmax

    Time frame: Day 3

  13. Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam

    PK parameter: Cmax

    Time frame: Day 3

  14. Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam

    PK parameter: AUC (0-last)

    Time frame: Day 3

  15. Oral pharmacokinetics (PK) of TEV-56286

    PK parameter: Trough concentration for TEV-56286

    Time frame: Day 3-18

  16. Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam

    PK parameter: Tmax

    Time frame: Day 18

  17. Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam

    PK parameter: Cmax

    Time frame: Day 18

  18. Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam

    PK parameter: Cmin

    Time frame: Day 18

  19. Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam

    PK parameter: Cavg

    Time frame: Day 18

  20. Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam

    PK parameter: AUC (0-tau)

    Time frame: Day 18

  21. Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam

    PK parameter: AUC (0-last)

    Time frame: Day 18

  22. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: Tmax

    Time frame: Day 19

  23. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: Cmax

    Time frame: Day 19

  24. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: Cmin

    Time frame: Day 19

  25. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: Cavg

    Time frame: Day 19

  26. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: AUC (0-tau)

    Time frame: Day 19

  27. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: AUC (0-last)

    Time frame: Day 19

  28. Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286

    PK parameter: Trough concentration for fluvoxamine

    Time frame: Day 15-19

  29. Oral pharmacokinetics (PK) of TEV-56286 after first dose administered as part of repeated administration

    PK parameter: Tlag for TEV-56286

    Time frame: Day 1

  30. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: Tmax

    Time frame: Day 1, Day 14

  31. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: Cmax

    Time frame: Day 1, Day 14

  32. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: AUC (0-tau)

    Time frame: Day 1, Day 14

  33. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: lambda-z

    Time frame: Day 1, Day 14

  34. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: T1/2

    Time frame: Day 1, Day 14

  35. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: CL/F

    Time frame: Day 1, Day 14

  36. Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose

    PK parameter: Vz/F

    Time frame: Day 1, Day 14

  37. Oral pharmacokinetics (PK) of TEV-56286 following multiple dose

    PK parameter: AUC (0-last)

    Time frame: Day 14

  38. Oral pharmacokinetics (PK) of TEV-56286 following multiple dose

    PK parameter: Cmin

    Time frame: Day 14

  39. Oral pharmacokinetics (PK) of TEV-56286 following multiple dose

    PK parameter: Cavg

    Time frame: Day 14

  40. Oral pharmacokinetics (PK) of TEV-56286 following multiple dose

    PK parameter: Accumulation ratio

    Time frame: Day 14

  41. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: Tmax

    Time frame: Day 1, Day 3, Day 18

  42. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: Cmax

    Time frame: Day 1, Day 3, Day 18

  43. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: AUC (0-last)

    Time frame: Day 1, Day 3, Day 18

  44. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: AUC (0-inf)

    Time frame: Day 1, Day 3, Day 18

  45. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: lambda-z

    Time frame: Day 1, Day 3, Day 18

  46. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: T1/2

    Time frame: Day 1, Day 3, Day 18

  47. Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam

    PK parameter: parent: metabolite ratio

    Time frame: Day 1, Day 3, Day 18

  48. Incidence of treatment-emergent adverse events including clinically significant changes in vital signs, ECGs and safety labs

    adverse events and clinically significant changes in vital signs, ECGs and safety labs

    Time frame: Day 1 up to follow up visit (5-11 days post last TEV-56286 dose)

  49. Number of participants reporting use of concomitant medications

    Number of participants reporting use of concomitant medications

    Time frame: Day 1 up to follow up visit (5-11 days post last TEV-56286 dose)

  50. Columbia-Suicide Severity Rating Scale (C-SSRS) total score

    Columbia-Suicide Severity Rating Scale (C-SSRS) total score

    Time frame: Day 3 to day 21

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Publications

  • Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, Wegrzynowicz M, Dalley JW, Langer S, Ryazanov S, Leonov A, Griesinger C, Schmidt F, Weckbecker D, Prager K, Matthias T, Giese A. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine. 2022 Jun;80:104021. doi: 10.1016/j.ebiom.2022.104021. Epub 2022 Apr 29. PubMed 35500536 ↗
  • Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bahr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Botzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125(6):795-813. doi: 10.1007/s00401-013-1114-9. Epub 2013 Apr 19. PubMed 23604588 ↗
  • Drug Interaction Studies M12. ICH Harmonised Guideline. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Draft version endorsed on 24 May 2022.
  • Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. US Food and Drug Administration. 07 Jul 2020. Available online: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/clinical-drug-interaction-studiescytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (accessed 23 Jun 2022).

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jan 2023, 4 months.

Of 25 phase 1 interventional studies under Multiple System Atrophy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 55. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Sep 8, 2022
StartActual
Sep 12, 2022
Primary completionActual
Jan 28, 2023
CompletionActual
Feb 10, 2023
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05532358
Lead sponsor
MODAG GmbH
Collaborators
Aptuit, Quotient Sciences, Teva Pharmaceutical Industries, Ltd.
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Sep 12, 2022
Primary completion
Jan 28, 2023
Completion
Feb 10, 2023
Last update
Mar 23, 2023

Study contacts

Nand Singh, MD
principal investigator · Quotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emrusolmin · Fluvoxamine

Start the discussion